Vertex Pharma (VRTX) Tops Q3 EPS by 30c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $516.44 -1.77%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.38, $0.30 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.77 billion versus the consensus estimate of $2.69 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.8-10.9 billion, versus the consensus of $10.759 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- JPMorgan Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
